IP Verse

Administration Of Gamma Hydroxybutyrate With Monocarboxylate Transporters - EP3335708

The patent EP3335708 was granted to Jazz Pharmaceuticals Ireland on Dec 11, 2019. The application was originally filed on Feb 28, 2014 under application number EP17200764A. The patent is currently recorded with a legal status of "Revoked".

EP3335708

JAZZ PHARMACEUTICALS IRELAND
Application Number
EP17200764A
Filing Date
Feb 28, 2014
Status
Revoked
Dec 13, 2024
Publication Date
Dec 11, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TER MEER STEINMEISTER & PARTNER PATENTANWALTE MBBSep 11, 2020TER MEER STEINMEISTER & PARTNERADMISSIBLE
HEXALSep 10, 2020MAIWALDADMISSIBLE
ZENTIVASep 2, 2020GREINERADMISSIBLE
HOFFMANN EITLEMar 16, 2020HOFFMANN EITLEADMISSIBLE

Patent Citations (36) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS20080264709
DESCRIPTIONWO2009US61312
DESCRIPTIONWO2010US33572
DESCRIPTIONDD237309
DESCRIPTIONGB1522450
DESCRIPTIONGB922029
DESCRIPTIONGB980279
DESCRIPTIONUS2009137565
DESCRIPTIONUS2012076865
DESCRIPTIONUS3325361
DESCRIPTIONUS3385886
DESCRIPTIONUS4155929
DESCRIPTIONUS4393236
DESCRIPTIONUS5380937
DESCRIPTIONUS5758095
DESCRIPTIONUS5833599
DESCRIPTIONUS5845255
DESCRIPTIONUS6014631
DESCRIPTIONUS6067524
DESCRIPTIONUS6112182
DESCRIPTIONUS6317719
DESCRIPTIONUS6356873
DESCRIPTIONUS6472431
DESCRIPTIONUS6780889
DESCRIPTIONUS7072840
DESCRIPTIONUS7262219
DESCRIPTIONUS7668730
DESCRIPTIONUS7765106
DESCRIPTIONUS7765107
DESCRIPTIONUS7797171
DESCRIPTIONUS7851506
DESCRIPTIONUS7895059
DESCRIPTIONUS8263650
DESCRIPTIONUS8324275
OPPOSITIONUS6780889
OPPOSITIONWO2014134380

Non-Patent Literature (NPL) Citations (117) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- ARENA et al., "Absorption of Sodium y-Hydroxybutyrate and Its Prodrug y-Butyrolactone: Relationship between In Vitro Transport and In Vivo Absorption", J. Pharmaceutical Sciences, (19800000), vol. 69, no. 3, pages 356 - 358
DESCRIPTION- AULER et al., "Diclofenac Plasma Protein Binding: PK-PD Modelling in Cardiac Patients Submitted to Cardiopulmonary Bypass", Braz. J. Med. Bio. Res., (19970000), vol. 30, pages 369 - 374
DESCRIPTION- BANERJEE et al., "Presynaptic Gamma-Hydroxybutyric Acid (GHB) and Gamma-Aminobutyric Acids (GABA ) Receptor-Mediated Release of GABA and glutamate (GLU) in Rat Thalamic Ventrobasal Nucleus (VB): A Possible Mechanism for the Generation of Absence-Like Seizures Induced by GHB", J. Pharmacol. Exp. Ther., (19950000), vol. 273, no. 3, pages 1534 - 1543
DESCRIPTION- BEDARD et al., "Nocturnal γ-Hydroxybutyrate. Effect on Periodic Leg Movements and Sleep Organization of Narcoleptic Patients", Clin. Neuropharmacol., (19890000), vol. 12, no. 1, pages 29 - 36
DESCRIPTION- BROUGHTON et al., "The Treatment of Narcolepsy-Cataplexy with Nocturnal Gamma-Hydroxybutyrate", Le Journal Canadien Des Sciences Neurologiques, (19790000), vol. 6, no. 1, pages 1 - 6, XP002083192
DESCRIPTION- "Drug Metabolism", GONZALEZ et al., Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, (20060000), pages 71 - 91
DESCRIPTION- FERRARA et al., "Pharmacokinetics of Gamma-hydroxybutyric Acid in Alcohol Dependent Patients after Single and Repeated Oral Doses", Br. J. Clin. Pharmacol., (19920000), vol. 34, no. 3, pages 231 - 5
DESCRIPTION- GALLIMBERTI et al., "Clinical Efficacy of Gamma-Hydroxybutyric Acid in Treatment of Opiate Withdrawal", Eur Arch Psychiatry Clin Neurosci, (19940000), vol. 244, pages 113 - 114
DESCRIPTION- GALLIMBERTI et al., "Gamma-Hydroxybutyric Acid for Treatment of Alcohol Withdrawal Syndrome", The Lancet, (19890900), vol. 30, pages 787 - 789
DESCRIPTION- GALLIMBERTI et al., "Gamma-Hydroxybutyric Acid for Treatment of Opiate Withdrawal Syndrome", Neuropsychopharmacology, (19930000), vol. 9, no. 1, pages 77 - 81
DESCRIPTION- GALLIMBERTI et al., "Gamma-Hydroxybutyric Acid in the Treatment of Alcohol Dependence: A Double-Blind Study", Alcoholism: Clinical and Experimental Research, (19920000), vol. 16, no. 4, pages 673 - 676
DESCRIPTION- GERRA et al., "Flumazenil Effects on Growth Hormone Response to Gamma-Hydroxybutyric Acid", Internat. Clin. Psychopharm., (19940000), vol. 9, pages 211 - 215
DESCRIPTION- GESSA et al., "Gamma-Hydroxybutyric Acid in the Treatment of Alcohol Dependence", Clin. Neuropharm.--Supplement, (19920000), vol. 15, no. 1, pages 303A - 304A
DESCRIPTION- HALESTRAP et al., "The SLC16 Gene Family-From Monocarboxylate Transporters (MCTs) to Aromatic Amino Acid Transporters and Beyond", Pflugers Arch., (20040000), vol. 447, no. 5, pages 619 - 628
DESCRIPTION- HASAN et al., "Pharmacokinetics of Diclofenac Sodium in Normal Man", Pakistan Jour. Pharmaceutical Sciences, (20050000), vol. 18, no. 1, pages 18 - 24
DESCRIPTION- HASENBOS et al., "Anaesthesia for bullectomy", Anaesthesia, (19850000), vol. 40, pages 977 - 980
DESCRIPTION- HECHLER et al., "Extracellular Events Induced by y-Hydroxybutyrate in Striatum: A Microdialysis Study", J. Neurochem., (19910000), vol. 56, no. 3, pages 938 - 944
DESCRIPTION- HENRY, T.R., "The History of Divalproex in Clinical Neuroscience", Psychopharmacology Bulletin, (20030000), vol. 37, no. 2, pages 5 - 16
DESCRIPTION- LABORIT, H., "Gamma-Hydroxybutyrate, Succinic Semialdehyde and Sleep", Laboratoire d'Eutonologie, Hopital Boucicaut, (19730000), pages 257 - 274
DESCRIPTION- LADINSKY et al., "Mode of Action of Gamma-Butyrolactone on the Central Cholinergic System", Naunyn-Schmiedeberg's Arch. Pharmacal., (19830000), vol. 322, pages 42 - 48
DESCRIPTION- LAMMERS et al., "Gammahydroxybutyrate and Narcolepsy: A Double-Blind Placebo-Controlled Study", Sleep, (19930000), vol. 16, no. 3, pages 216 - 220
DESCRIPTION- LAPIERRE et al., "The Effect of Gamma-Hydroxybutyrate: A Double-Blind Study of Normal Subjects", Sleep Research, (19880000), vol. 17, page 99
DESCRIPTION- LAPIERRE et al., "The Effect of Gamma-Hydroxybutyrate on Nocturnal and Diurnal Sleep of Normal Subjects: Further Considerations on REM Sleep-Triggering Mechanisms", Sleep, (19900000), vol. 13, no. 1, pages 24 - 30
DESCRIPTION- LETTIERI et al., "Improved Pharmacological Activity via Pro-Drug Modification: Comparative Pharmacokinetics of Sodium γ-Hydroxybutyrate and y-Butyrolactone", Research Communications In Chemical Pathology and Pharmacology, (19780000), vol. 22, no. 1, pages 107 - 118
DESCRIPTION- MAITRE et al., "A Specific y-Hydroxybutyrate Receptor Ligand Possesses both Antagonistic and Anticonvulsant Properties", J. Pharmacol. Exp. Ther., (19900000), vol. 255, no. 2, pages 657 - 663
DESCRIPTION- MAITRE et al., "Mecanismes d'action d'un medicament detourne: le γ-hydroxybutyrate'' ('A mechanism for gamma-hydroxybutyrate (GHB) as a drug and a substance of abuse", Med Sci (Paris), (20050000), vol. 21, no. 3, pages 284 - 9
DESCRIPTION- MAMELAK et al., "Sleep-Inducing Effects of Gammahydroxybutyrate", The Lancet, (19730000), vol. 302, no. 7824, pages 328 - 329
DESCRIPTION- MAMELAK et al., "The Effects of y-Hydroxybutyrate on Sleep", Biol. Psychiatry, (19770000), vol. 12, no. 2, pages 273 - 288, XP000600034
DESCRIPTION- MAMELAK et al., "Treatment of Narcolepsy and Sleep Apnea with Gammahydroxybutyrate: A Clinical and Polysomnographic Case Study", Sleep, (19810000), vol. 4, no. 1, pages 105 - 111
DESCRIPTION- MAMELAK, "Gammahydroxybutyrate: An Endogenous Regulator of Energy Metabolism", Neuroscience and Biobehav. Reviews, (19890000), vol. 13, pages 187 - 198
DESCRIPTION- NEMA et al., "Excipients and Their Use in Injectable Products", PDA J. Pharm. Sci. Technol., (19970000), vol. 51, no. 4, pages 166 - 171
DESCRIPTION- PALATINI et al., "Dose-Dependent Absorption and Elimination of Gamma-Hydroxybutyric Acid in Healthy Volunteers", Eur. J. Clin. Pharmacol., (19930000), vol. 45, pages 353 - 356
DESCRIPTION- SCHARF et al., "The Effects and Effectiveness of y-Hydroxybutyrate in Patients with Narcolepsy", J. Clin. Psychiatry, (19850000), vol. 46, no. 6, pages 222 - 225
DESCRIPTION- SCRIMA et al., "Gamma-Hydroxybutyrate Effects on Cataplexy and Sleep Attacks in Narcoleptics", Sleep Res., (19870000), vol. 16, page 134
DESCRIPTION- SCRIMA et al., "The Effects of y-Hydroxybutyrate on the Sleep of Narcolepsy Patients: A Double-Blind Study", Sleep, (19900000), vol. 13, no. 6, pages 479 - 490
DESCRIPTION- SERIES et al., "Effects of Enhancing Slow-Wave Sleep by Gamma-Hydroxybutyrate on Obstructive Sleep Apnea", Am. Rev. Respir. Dis., (19920000), pages 1378 - 1383
DESCRIPTION- SMOLDERS et al., "Tonic GABA-ergic Modulation of Striatal Dopamine Release Studied by In Vivo Microdialysis in the Freely Moving Rat", Eur. J. Pharmacol., (19950000), vol. 284, no. 1-2, pages 83 - 91
DESCRIPTION- STRONG, "y-Hydroxybutyric Acid and Intracranial Pressure", The Lancet, (19840000), vol. 1, no. 8389
DESCRIPTION- VAN DEN BOGERT et al., "Placentatransfer of 4-Hydroxybutyric Acid in Man", Anesthesiology and Intensive Care Medicine, (19780000), vol. 110, pages 55 - 64
DESCRIPTION- VICKERS, M.D., "Gammahydroxybutyric Acid", Int. Anesth. Clinic, (19690000), vol. 7, pages 75 - 89
DESCRIPTION- WASZKIELEWICZ et al., "y-Hydrobutyric Acid (GHB) and its Chemical Modifications: A Review of the GHBergic System", Pol J Pharmacol., (20040000), vol. 56, no. 1, pages 43 - 49
DESCRIPTION- ROSENBERG, G., "The Mechanisms of Action of Valproate in Neuropsychiatric Disorders: Can We See the Forest for the Trees?", Cel. Mol. Life Sci., (20070000), vol. 64, no. 16, doi:doi:10.1007/s00018-007-7079-x, pages 2090 - 2103, XP019536863
DESCRIPTION- LEE, C.R., "Evidence for the β-Oxidation of Orally Administered 4-Hydroxybutyrate in Humans", Biochem. Med., (19770000), vol. 17, doi:doi:10.1016/0006-2944(77)90034-5, pages 284 - 291, XP026177020
DESCRIPTION- ROTH et al., "y-Butyrolactone and γ-Hydroxybutyric Acid-I Distribution and Metabolism", Biochemical Pharmacology, (19660000), vol. 15, doi:doi:10.1016/0006-2952(66)90045-1, pages 1333 - 1348, XP023727801
DESCRIPTION- SCRIMA et al., "Efficacy of Gamma-Hydroxybutyrate versus Placebo in Treating Narcolepsy—Cataplexy: Double-Blind Subjective Measured", Biol. Psychiatry, (19890000), vol. 26, doi:doi:10.1016/0006-3223(89)90048-6, pages 331 - 343, XP025418901
DESCRIPTION- YAMADA et al., "Effect of Butyrolactone and Gamma-Hydroxybutyrate on the EEG and Sleep Cycle in Man", Electroenceph. Clin. Neurophysiol., (19670000), vol. 22, doi:doi:10.1016/0013-4694(67)90064-8, pages 558 - 562, XP024292630
DESCRIPTION- ROTH et al., "y-Butyrolactone and y-Hydroxybutyric Acid—II The Pharmacologically Active Form", Int. J. Neropharmacol., (19660000), vol. 5, doi:doi:10.1016/0028-3908(66)90007-4, pages 421 - 428, XP023763604
DESCRIPTION- KURIYAMA et al., "Blood-Brain Barrier to H3-γ-Aminobutyric Acid in Normal and Amino Oxyacetic Acid-Treated Animals", Neuropharmacology, (19710000), vol. 10, doi:doi:10.1016/0028-3908(71)90013-X, pages 103 - 108, XP025490209
DESCRIPTION- DIMITRIJEVIC et al., "Drosophila GABA Receptors are Involved in Behavioral Effects of y-Hydroxybutyric Acid (GHB", Eur. J. Pharmacol., (20050000), vol. 519, no. 3, doi:doi:10.1016/j.ejphar.2005.07.016, pages 246 - 252, XP005071265
DESCRIPTION- WU et al., "γ-Hydroxybutyric acid (GHB) and y-aminobutyric acids receptor (GABA R) binding sites are distinctive from one another: molecular evidence", Neuropharmacology, (20040000), vol. 47, no. 8, doi:doi:10.1016/j.neuropharm.2004.08.019, pages 1146 - 56, XP004655801
DESCRIPTION- CASH et al., "y-Hydroxybutyrate Receptor Function Studied by the Modulation of Nitric Oxide Synthase Activity in Rat Frontal Cortex Punches", Biochemical Pharmacology, (19990000), vol. 58, no. 11, doi:doi:10.1016/S0006-2952(99)00265-8, pages 1815 - 1819, XP000876980
OPPOSITION- Anonymous, "Important safety information Xyrem", xyrem.com, (20130219), xyrem.com, URL: https://web.archive.org/web/20130219174039/ http://www.xyrem.com/warning/warning5.html, (20221012), XP055970231
OPPOSITION- Anonymous, "Information about Xyrem.com", Whois lookup, (20001109), Whois lookup, (20221012), XP055970235
OPPOSITION- Anonymous, "PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION FOR XYREM®", XYREM, (20180611), XYREM, (20221012), XP055970240
OPPOSITION- Anonymous, "XYREM is an FDA-approved treatment for both cataplexy and EDS in narcolepsy", XYREM, (20111128), URL: https://web.archive.org/web/20111128230754/http://www.xyrem.com/he, XP055765881
OPPOSITION- anonymous, "XYREM is an FDA-approved treatment for both cataplexy and EDS in narcolepsy", XYREM, (20121215), URL: https://web.archive.org/web/20121215004227/http://www.xyrem.com/healthcare-professionals, XP055765880
OPPOSITION- BOJARSKI J, WASZKIELEWICZ A, "Gamma-Hydroxybutyric Acid (GHB) and Its Chemical Mdoficiations: A Review of the GHBergic System", POLISH JOURNAL OF PHARMACOLOGY, (20040101), vol. 56, no. 1, ISSN 1230-6002, pages 43 - 49, XP008091834
OPPOSITION- CASH, C. D., "Gammahydroxybutyrate: An Overview of the Pros and Cons for it Being a Neurotransmitter And/Or a Useful Therapeutic Agent", Neurosci. Behav. Rev., (19940000), vol. 18, no. 2, pages 291 - 304, XP055517014
OPPOSITION- CASH, C.-D., "Gammahydroxybutyrate: An Overview of the Pros and Cons for it being a Neurotransmitter and/or a Useful Therapeutic Agent", Neurosci. Behav. Rev., (19940000), vol. 18, pages 291 - 304, XP055517014
OPPOSITION- "Depakene®", Highlights of Prescribing Information -, (20130200), XP055744992
OPPOSITION- ELLER, M. et al., "Evaluation of drug-drug interactions of sodium oxybate with divalproex: Results from a pharmacokinetic/pharmacodynamics study", Sleep Medicine, (20130000), vol. 14, pages e302 - e303, XP055517276
OPPOSITION- ELLER, M. et al., "Evaluation of drug-drug interactions of sodium oxybate with divalproex: Results from a pharmacokinetic/pharmacodynamic study", Sleep Medicine, (20130000), vol. 14, no. 1, pages e302 - e303, XP055517276
OPPOSITION- Ema, "Guideline on the Investigation of Drug Interactions", CPMP/EWP/560/95/Rev. 1 - Corr., (20100422), pages 1 - 38, CPMP/EWP/560/95/Rev. 1 - Corr., URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf, (20180925), XP055509801
OPPOSITION- Excerpt from KEGG database (Kyoto Encyclopedia of Genes and Genomes, (20180712), URL: https://www.genome.jp/dbget-bin/www_bget?ec:1.1.1.19, XP055745021
OPPOSITION- FDA, "Depakote (divalproex sodium) Tablets for Oral use", FDA - HIGHLIGHTS OF PRESCRIBING INFORMATION, (20130200), pages 1 - 51, XP055765877
OPPOSITION- FDA, "Xyrem® (sodium oxybate) oral solution CIII", FDA - HIGHLIGHTS OF PRESCRIBING INFORMATION, (20121200), pages 1 - 30, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021196s013lbl.pdf, XP055765878
OPPOSITION- FULLER et al., "From Club Drug to Orphan Drug: Sodium Oxybate Xyrem for the Treatment of Cataplexy", Pharmacotherapy, (20030000), vol. 23, no. 9, pages 1205 - 1209, XP055123175
OPPOSITION- George, C.F.P. ; Feldman, N. ; Inhaber, N. ; Steininger, T.L. ; Grzeschik, S.M. ; Lai, C. ; Zheng, Y., "A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing", Sleep Medicine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20100101), vol. 11, no. 1, ISSN 1389-9457, pages 38 - 42, XP026823110
OPPOSITION- GEORGE et al., "A safety trial of sodium oxybate in patients with obstructive sleep apnea: acute effect on sleep-disordered breathing", Sleep Medicine, (20100000), vol. 11, pages 38 - 42, XP026823110
OPPOSITION- "glucuronate reductase", KEGG ENZYME, (20180712), Database accession no. 1.1.1.19, URL: genome, XP055765873
OPPOSITION- Goswamy, "Sodium Oxybate", Narcolepsy A Clinical Guide, (20160101), page 89, XP055713479
OPPOSITION- "Guidelines on the investigation of drug interactions", EUROPEAN MEDICINES AGENCY EMA,, (20120000), XP055770989
OPPOSITION- HECHLER, V. et al., "y- Hydroxy butyrate Conversion into GABA InducesDisplacement of GABAb Binding that is Blocked by Valproate and Ethosuximide1", J. Pharmacol. Exp. Therap., (19970000), vol. 281, no. 2, pages 753 - 760, XP055745030
OPPOSITION- "Highlights of Prescribing Information - Stavzor®", NDA 22-152/Stavzor, (20080700), XP055744372
OPPOSITION- KAUFMAN, E.E. et al., "EVIDENCE FOR THE PARTICIPATION OF A CYTOSOLIC NADP-DEPENDENT OXIDOREDUCTASE IN THE CATABOLISM OF GAMMA HYDROXYBUTYRATE IN-VIVO", Journal of Neurochemistry, (19870000), vol. 48, no. 6, pages 1935 - 1941, XP002607528
OPPOSITION- KOTHARE et al., "Pharmacotherapy of Narcolepsy: Focus on Sodium Oxybate", Clinical Medicine Insights, Therapeutics, (20100000), vol. 2, pages 37 - 52, XP055516920
OPPOSITION- "Lithium Carbonate Tablets USP", Roxane Laboratories, (20111000), XP055516882
OPPOSITION- "Metabolism and distribution of gamma hydroxybutyrate in the brain", Gamma-Hydroxybutyrate: Molecular, Functional and Clinical Aspects, London, (20020000), XP055745044
OPPOSITION- MICHEL BILLIARD, "Narcolepsy: Current treatment options and future approaches, Neuropsychiatric Disease and Treatment", Neuropsychiatr Dis Treat ., (20080606), vol. 4, no. 3, pages 557 - 566, XP055765874
OPPOSITION- WASZKIELEWICZ, A. et al., "Gamma-Hydroxybutyric Acid (GHB) and Its Chemical Mdoficiations: A Review of the GHBergic System", Pol. J. Pharmacol., (20040000), vol. 56, no. 1, pages 43 - 49, XP008091834
OPPOSITION- WASZKIELEWICZ, A. et al., "y-Hydroxybutyric Acid (GHB) and its Chemical modifications: A Review of the GHBergic System", Pol. J. Pharmacol., (20040000), vol. 56, pages 43 - 49, XP008091834
OPPOSITION- WASZKIELEWISCZ et al., "y-Hydroxybutyric acid (GHb) and its chemical modifications: a review of the GHBergic system", Polish Journal of Pharmacology, (20040000), vol. 56, pages 43 - 49, XP008091834
OPPOSITION- "Xyrem 500 mg/mL oral solution", SUMMARY OF PRODUCT CHARACTERISTICS
OPPOSITION- "xyrem 500", product information
OPPOSITION- "Xyrem®", Highlights of Prescribing Information, (20121200), XP055744989
OPPOSITION- Xyrem® package insert in the United States (cited by Patentee during prosecution
OPPOSITION- "XYREM® (sodium oxybate) oral solution", (20160900), XP055770970
OPPOSITION- "Xyrem® (sodium oxybate) oral solution CIII", FDA - HIGHLIGHTS OF PRESCRIBING INFORMATION, (20121200), XP055765878
OPPOSITION- "Xyrem (sodium oxybate) oral solution", FDA Approved Labeling, (20051100), XP055770975
OPPOSITION- KAUFMAN, E.-E. et al., "An Overview of gamma-Hydroxybutyrate Catabolism: The Role of the Cytosolic NADP+-Dependent Oxidoreductase EC 1.1.1.19 and of a Mitochondrial Hydroxyacid-Oxoacid Transhydrogenase in the Initial, Rate-Limiting Step in This Pathway", Neurochem. Res., (19910101), vol. 16, no. 9, pages 965 - 974, XP008082252
OPPOSITION- KAUFMAN, E. E. et al., "An overview of y-hydroxybutyrate catabolism: The role of the cytosolic NADP+-dependent oxidoreductase EC 1.1.1.19 and of a mitochondrial hydroxyacid-oxiacid transhydrogenase in the initial, rate-limiting step in this pathway", Neurochem. Res., (19910000), vol. 16, no. 9, pages 965 - 974, XP008082252
OPPOSITION- Indranil Bhattacharya ; Kathleen M. K. Boje, "Potential γ-Hydroxybutyric acid (GHB) Drug Interactions Through Blood-Brain Barrier Transport Inhibition: A Pharmacokinetic Simulation-Based Evaluation", Journal of Pharmacokinetics and Pharmacodynamics, Kluwer Academic Publishers-Plenum Publishers, Ne, Ne, (20060829), vol. 33, no. 5, doi:10.1007/s10928-006-9029-x, ISSN 1573-8744, pages 657 - 681, XP019401210
OPPOSITION- Samuel A. Roiko, Nisha Vijay, Melanie A. Felmlee, Marilyn E. Morris, "Brain Extracellular γ-hydroxybutyrate Concentrations are Decreased by L-lactate in Rats: Role in the Treatment of Overdoses", Pharmaceutical Research, Springer New York LLC, US, US, (20130501), vol. 30, no. 5, doi:10.1007/s11095-013-0973-z, ISSN 0724-8741, pages 1338 - 1348, XP055713484
OPPOSITION- SNEAD, O. C. et al., "Effect of acute and chronic anticonvulsant administration on endogenous γ-hydroxybutyrate in rat brain", Neuropharmacology, (19800000), vol. 19, no. 1, pages 47 - 52, XP055517010
OPPOSITION- SNEAD, O.-D. et al., "Effect of Acute and Chronic Anticonvulsant Administration on Endogenous gamma-Hydroxybutyrate in Rat Brain", Neuropharmacology, (19790000), vol. 19, doi:10.1016/0028-3908(80)90165-3, pages 47 - 52, XP055517010
OPPOSITION- VAYER, P. et al., "Is the anticonvulsant mechanism of valproate linked to its interaction with the cerebral @c-hydroxybutyrate system", Trends in Pharmacological Sci., (19880000), vol. 9, no. 4, pages 127 - 129, XP023855737
OPPOSITION- VAYER, P. et al., "Is the Anticonvulsant Mechanism of Valproate Linked to its Interaction with the Cerebral gamma-Hydroxybutyrate System?", Trends in Pharmacol. Sci., (19880401), vol. 9, no. 4, pages 127 - 129, XP025843177
OPPOSITION- MAITRE, M., "THE GAMMA-HYDROXYBUTYRATE SIGNALLING SYSTEM IN BRAIN: ORGANIZATION AND FUNCTIONAL IMPLICATIONS TI - THE GAMMA-HYDROXYBUTYRATE SIGNALLING SYSTEM IN BRAIN: ORGANIZATION AND FUNCTIONAL IMPLICATIONS", Prog. Neurobiol., (19970000), vol. 51, no. 3, pages 337 - 361, XP000877100
OPPOSITION- MAITRE, "The y-Hydroxybutyrate signaling system in brain: organization and functional implications", Progress in Neurobiology, (19970000), vol. 51, pages 337 - 361, XP000877100
OPPOSITION- LOSCHER, W., "Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action", Progress Neurobiol., (19990000), vol. 58, pages 31 - 59, XP055517204
OPPOSITION- SHINKA, T. et al., "Effect of valproic acid on the urinary metabolic profile of a patient with succinic semialdehyde dehydrogenase deficiency", J. Chromatogr. B., (20030000), vol. 792, no. 1, pages 99 - 106, XP004431819
OPPOSITION- ELI, M. et al., "Endogenous gamma-Hydroxybutyrate in Rat Brain Areas: Postmortem Changes and Effects of Drugs Interfering with gamma-Aminobutyric Acid Metabolism", J. Neurochem., (19830000), vol. 41, doi:10.1111/j.1471-4159.1983.tb04770.x, pages 524 - 530, XP055517246
OPPOSITION- ELI, M. et al., "Endogenous gamma-Hydroxybutyrate in Rat Brain Areas: Postmortem Changes and Effects of Drugs Interfering with gamma-Aminobutyric Acid Metabolism", J. Neurochem., (19830000), vol. 41, no. 2, pages 524 - 530, XP055517246
OPPOSITION- Daniel Pardi, Black Jed, "γ-Hydroxybutyrate/Sodium Oxybate Neurobiology, and Impact on Sleep and Wakefulness", CNS DRUGS, ADIS INTERNATIONAL, AUCKLAND, NZ, AUCKLAND, NZ, (20061201), vol. 20, no. 12, doi:10.2165/00023210-200620120-00004, ISSN 1172-7047, pages 993 - 1018, XP055516866
OPPOSITION- PARDI, D. et al., "y-Hydroxybutyrate/Sodium Oxybate Neurobiology, and Impact on Sleep and Wakefulness", CNS Drugs, (20060000), vol. 20, doi:10.2165/00023210-200620120-00004, pages 993 - 1018, XP055516866
OPPOSITION- PARDI, D. et al., "γ-Hydroxybutyrate/Sodium Oxybate Neurobiology, and Impact on Sleep and Wakefulness", CNS Drugs, (20060000), vol. 20, no. 12, pages 993 - 1018, XP055516866
OPPOSITION- PARDI et al., "y-Hydroxybutyrate/Sodium Oxybate", CNS Drugs, (20060000), vol. 20, no. 12, doi:10.2165/00023210-200620120-00004, pages 993 - 1018, XP055516866
OPPOSITION- SARKANEN et al., "Psychosis in patients with narcolepsy as an adverse effect of sodium oxybate", frontiers in neurology, (20140000), vol. 5, XP055713476
OPPOSITION- Tomi Sarkanen, Valter Niemelã¤, Anne-Marie Landtblom, Markku Partinen, "Psychosis in Patients with Narcolepsy as an Adverse Effect of Sodium Oxybate", Frontiers in Neurology, vol. 5, doi:10.3389/fneur.2014.00136, XP055713476
OPPOSITION- Marilyn E Morris, "Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases γ-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study", Journal of Clinical Toxicology, vol. 01, no. 02, doi:10.4172/2161-0495.1000105, XP055713482
OTHER- Anna WASZKIELEWICZ, Jacek BOJARSKI, "Gamma-Hydroxybutyric Acid (GHB) and Its Chemical Mdoficiations: A Review of the GHBergic System", Pol J Pharmacol., (20040000), vol. 56, no. 1, pages 43 - 49, XP008091834
OTHER- Anonymous, "Possible Xyrem side effects in 53 year old male", DrugLib.com, URL: http://www.druglib.com/reported-side-effects/xyrem/reaction_mania/
OTHER- Indranil BHATTACHARYA, Kathleen M.K. BOJE, "Potential γ-Hydroxybutyric acid (GHB) Drug Interactions Through Blood-Brain Barrier Transport Inhibition: A Pharmacokinetic Simulation-Based Evaluation", J Pharmacokinet Pharmacodyn., (20060000), vol. 33, no. 5, pages 657 - 681, XP019401210
SEARCH- Fuller D ET AL, "From Club Drug to Orphan Drug: Sodium Oxybate (Xyrem) for the Treatment of Cataplexy", (20030901), URL: http://onlinelibrary.wiley.com/store/10.1592/phco.23.10.1205.32756/asset/phco.23.10.1205.32756.pdf?v=1&t=hwd6sj5s&s=83f56be5dea98a39c083d39d2396ab75a192f4ac, (20140613), XP055123175 [A] 1 * abstract *
SEARCH- Viviane Hechler ET AL, "gamma-Hydroxybutyrate Conversion into GABA Induces Displacement of GABA B Binding that is Blocked by Valproate and Ethosuximide 1", (19970130), URL: http://jpet.aspetjournals.org/content/281/2/753.full.pdf#page=1&view=FitH, (20140613), XP055123267 [A] 1 * abstract *
SEARCH- PETRINE WELLENDORPH ET AL, "Phenylacetic acids and the structurally related non-steroidal anti-inflammatory drug diclofenac bind to specific [gamma]-hydroxybutyric acid sites in rat brain", FUNDAMENTAL & CLINICAL PHARMACOLOGY, (20090401), vol. 23, no. 2, doi:10.1111/j.1472-8206.2008.00664.x, ISSN 0767-3981, pages 207 - 213, XP055123069 [A] 1 * abstract *
SEARCH- BHATTACHARYA I ET AL, "GHB (GAMMA-HYDROXYBUTYRATE) CARRIER-MEDIATED TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, (20041001), vol. 311, no. 1, doi:10.1124/JPET.104.069682, ISSN 0022-3565, pages 92 - 98, XP009049440 [A] 1 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents